semaglutide dr phillips Why some are calling a new weight loss drug a game-changer GLP-1 Weight Loss Drugs: What

Our commitment to safety demands careful, precise patient screenings

10.1016/j.ymben.2020.03.00803.008 104 PrasadP

Gallbladder disease: Incretin-based therapies have been associated with an increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), as noted in the UK SmPCs for licensed comparators such as semaglutide and tirzepatide

They are not intended for human or animal consumption, diagnostic, therapeutic, or agricultural use

Statements Author contributions LC contributed in collecting bibliography, in writing the manuscript, and in conceiving and creating the figures

Amenorrhoea NICE Clinical Knowledge Summary